Publications by authors named "Jussi Pekka Koivunen"
Article Synopsis
- Systemic immune activation, indicated by elevated levels of C-reactive protein (CRP) and interleukin-6 (IL-6), affects immune responses in patients with non-small cell lung cancer (NSCLC) undergoing treatment with immune checkpoint inhibitors (ICIs).
- The study assessed the link between CRP levels, patient outcomes like overall survival (OS) and progression-free survival (PFS), and explored the immune mechanisms associated with these factors.
- Results indicated that patients with high CRP at baseline (CRP-H) had significantly poorer outcomes, including shorter OS and PFS, and that CRP-H was an independent predictor of increased mortality risk and lower disease response rate
Introduction: Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect of osimertinib on brain metastases in both T790M-positive and -negative patients.
View Article and Find Full Text PDFBackground: With the first and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with tetracyclines, but it is unknown whether the use of tetracyclines can increase the survival of non-small-cell lung cancer (NSCLC) patients treated with EGFR TKIs.
Methods: We collected all the patients (n=1271) who had reimbursement for EGFR TKIs (gefitinib, erlotinib and afatinib) in Finland 2011-2016, had purchased TKIs, and had data available at nationwide cancer registry.
Background: Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents.
Material And Methods: Discovery cohort consisted of patients who were treated with anti-programmed cell death protein-1 (PD-1) agents for advanced melanoma (MEL), non-small cell lung cancer (NSCLC) or renal and bladder cancers (GU) at Oulu University Hospital and had pretreatment C reactive protein (CRP), or neutrophil/lymphocyte values available.